Factors such as age and race/ethnicity might influence blood pressure (BP) response to drugs. Therapeutic response to the angiotensin-converting enzyme inhibitor @entity21594 used as add-on therapy to stable @entity460 channel blocker therapy with @entity1855 sustained release 240 mg was addressed in a racially/ethnically diverse group of 1,832 @entity101 @entity1 with @entity453 . Furthermore, the association with a polymorphism ( @entity7744 ) in the @entity7743 gene ( @entity7743 ) was tested. BP response was compared between groups using analysis of covariance after adjustment for covariates associated with BP response. Genotyping was performed using polymerase chain reaction and pyrosequencing. @entity21594 decreased mean unadjusted systolic and diastolic BPs by -9.1 +/- 17.3 (SD) and -4.1 +/- 10.1 mm Hg, respectively. The percentage of @entity1 with BP under control (<140/90 mm Hg) increased from 6.7% to 41.3% (p <0.0001). Adjusted BP response was significantly associated with age and baseline systolic and diastolic BP (p <0.0001). Whereas the decrease in systolic BP was more pronounced in younger @entity1 , the opposite was observed for diastolic BP decrease. Diastolic BP response was also significantly associated with race. Specifically, the adjusted diastolic BP decrease was significantly smaller in Hispanics and blacks than whites (p = 0.0032 and p = 0.0069, respectively). However, Hispanics achieved a decrease in systolic BP and an increase in BP control similar to the other ethnic groups. There was no genetic association between @entity7743 @entity7744 genotype and BP response. In conclusion, @entity21594 add-on therapy was effective in increasing BP control, with age and baseline BP associated with both systolic and diastolic BP response. Race was associated with diastolic BP response, although the difference is likely not to be clinically significant and @entity7743 genotype was not associated with BP response.

Factors influencing blood pressure response to XXXX add-on therapy in @entity1 taking verapamil SR (from the International Verapamil SR/ @entity21594 [INVEST] Study).

@entity1 :: ('9606', 'Species') :: ['patients'] @entity7744 :: ('c|SUB|A|1166|C', 'DNAMutation') :: ['1166A-->C'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertensive'] @entity1855 :: ('MESH:D014700', 'Chemical') :: ['verapamil'] @entity7743 :: ('185', 'Gene') :: ['angiotensin II type 1 receptor', 'AGTR1'] @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium'] @entity453 :: ('MESH:D003324', 'Disease') :: ['coronary artery disease'] @entity21594 :: ('MESH:C052035', 'Chemical') :: ['trandolapril', 'Trandolapril']
@entity21594 :: (MESH:C052035,Chemical) :: ['trandolapril']
